REDUCED HEART RATE RESPONSE TO EXERCISE IN ELDERLY
REDUCED HEART RATE RESPONSE TO EXERCISE IN ELDERLY
批准号:
6275410
负责人:
John G. Gerber
金额:
$3.14万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-12-01 至 1998-11-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
One of the consistent cardiovascular changes associated with aging is the
decrease in maximal heart rate to exercise. In the past, we have explored
the mechanism for this decrease by examining b-adrenoceptor change with
aging. Using adipocytes as a prototype cell that has both b1- and b2-
adrenoceptors, we could not identify any changes in b-adrenoceptor
sensitivity with aging. We then tested the hypothesis that excessive
adenosine release or sensitivity was the abnormality with aging that
results in the decrease in maximal heart rate. Using theophylline to
block adenosine receptors, we were unable to demonstrate that adenosine
had a major role in this down-regulated response in the elderly. This
present study explored the role of L-type calcium channels, and the effect
of blocking them with diltiazem, in the cardiovascular response to maximal
exercise with aging. The hypothesis was that if aging is associated with
a down-regulated L-type calcium channel, or the inability to keep the
calcium channel in an open state, then elderly subjects would have less of
a heart rate effect during exercise with diltiazem administration than the
young group. Thus, a group of healthy young and old men (n+8 in each) were
subjected to maximal exercise test twice, once with placebo and once after
diltiazem infusion. Our data were corrected to plasma concentration of
diltiazm. Indeed, we found that the young group had a greater decrease in
maximal heart rate to exercise than the old group (young:185 +/- with
placebo, 178 +/- with diltiazem; old 150 +/- with placebo, 148 +/- with
diiltiazm). When we correlated the plasma concentration of diltiazem at
the end of exercise with the change in maximal heart rate (placebo-
diltiazem) in the two age groups, the young group demonstrated a
significant correlation (p+0.05) With increasing change in heart rat to
increasing diltiazem concentration, while the old group had no such
correlation. These data suggest that one explanation for the reduced
maximal heart rate response with aging may very well be secondary to
abnormal calcium channels in pacemaker cells resulting in slower
depolarization to stimuli.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EFFECT OF COMBTHERW/FISH OIL SUPP&FENOFIBRATE ON TG LEVELS IN SBJCTS ON HAART
-
批准号:7377831
-
项目类别:
-
资助金额:$0.18万
-
财政年份:2006
-
负责人:John G. Gerber
-
依托单位:
ACTG A5165: STUDY OF DAPD VS DAPD + MMF IN TREATMENT-EXPERIENCED SUBJECTS
-
批准号:7200552
-
项目类别:
-
资助金额:$0.55万
-
财政年份:2005
-
负责人:John G. Gerber
-
依托单位:
PREDICTIVE VALUE OF PHARMACOKIN-ADJC12H/1C50 ON RESPONSE TO PROTEASE INHIBITORS
-
批准号:7200544
-
项目类别:
-
资助金额:$0.46万
-
财政年份:2005
-
负责人:John G. Gerber
-
依托单位:
EFFECT OF COMBTHERW/FISH OIL SUPP&FENOFIBRATE ON TG LEVELS IN SBJCTS ON HAART
-
批准号:7200606
-
项目类别:
-
资助金额:$0.83万
-
财政年份:2005
-
负责人:John G. Gerber
-
依托单位:
Predictive Value of Pharmacokin-Adj.C12h/1C50
-
批准号:6982162
-
项目类别:
-
资助金额:$0.2万
-
财政年份:2004
-
负责人:John G. Gerber
-
依托单位:
ACTG A5165: STUDY OF DAPD VS. DAPD + MMF IN TREATMENT
-
批准号:6982176
-
项目类别:
-
资助金额:$1.75万
-
财政年份:2004
-
负责人:John G. Gerber
-
依托单位:
ACTG 365 PHARMACOKINETIC INTERACTION OF INDINAVIR & RIFABUTIN
-
批准号:6504445
-
项目类别:
-
资助金额:$19.07万
-
财政年份:2000
-
负责人:John G. Gerber
-
依托单位:
RIFABUTIN PROBE TO MEASURE CYP3A4 ACTIVITY
-
批准号:6504417
-
项目类别:
-
资助金额:$19.07万
-
财政年份:2000
-
负责人:John G. Gerber
-
依托单位:
PROTEASE INHIBITORS AND METHADONE METABOLISM IN HIV +
-
批准号:6504440
-
项目类别:
-
资助金额:$19.07万
-
财政年份:2000
-
负责人:John G. Gerber
-
依托单位:
PROTEASE INHIBITORS AND METHADONE METABOLISM IN HIV +
-
批准号:6566292
-
项目类别:
-
资助金额:$19.07万
-
财政年份:2000
-
负责人:John G. Gerber
-
依托单位:
RIFABUTIN PROBE TO MEASURE CYP3A4 ACTIVITY
-
批准号:6566269
-
项目类别:
-
资助金额:$19.07万
-
财政年份:2000
-
负责人:John G. Gerber
-
依托单位:
ACTG 365 PHARMACOKINETIC INTERACTION OF INDINAVIR & RIFABUTIN
-
批准号:6566297
-
项目类别:
-
资助金额:$19.07万
-
财政年份:2000
-
负责人:John G. Gerber
-
依托单位:
PROTEASE INHIBITORS AND LIPID LOWERING AGENTS
-
批准号:6504424
-
项目类别:
-
资助金额:$19.07万
-
财政年份:2000
-
负责人:John G. Gerber
-
依托单位:
PROTEASE INHIBITORS AND LIPID LOWERING AGENTS
-
批准号:6566276
-
项目类别:
-
资助金额:$19.07万
-
财政年份:2000
-
负责人:John G. Gerber
-
依托单位:
ACTG 365 PHARMACOKINETIC INTERACTION OF INDINAVIR & RIFABUTIN
-
批准号:6304224
-
项目类别:
-
资助金额:$3.22万
-
财政年份:1999
-
负责人:John G. Gerber
-
依托单位:
ACTG 365 PHARMACOKINETIC INTERACTION OF INDINAVIR & RIFABUTIN
-
批准号:6263998
-
项目类别:
-
资助金额:$3.22万
-
财政年份:1998
-
负责人:John G. Gerber
-
依托单位:
AGE-RELATED RESPONSES IN ISOLATED FAT CELLS
-
批准号:6245206
-
项目类别:
-
资助金额:$2.65万
-
财政年份:1997
-
负责人:John G. Gerber
-
依托单位:
CHANGES IN BARORECEPTOR FUNCTION WITH AGING
-
批准号:6245205
-
项目类别:
-
资助金额:$2.65万
-
财政年份:1997
-
负责人:John G. Gerber
-
依托单位:
AGE RELATED CHANGES IN ADRENERGIC CLINICAL PHARMACOLOGY
-
批准号:2051121
-
项目类别:
-
资助金额:$20.85万
-
财政年份:1992
-
负责人:John G. Gerber
-
依托单位:
AGE-RELATED CHANGES IN ADRENERGIC CLINICAL PHARMACOLOGY
-
批准号:3121782
-
项目类别:
-
资助金额:$19.39万
-
财政年份:1992
-
负责人:John G. Gerber
-
依托单位:
海外基金